MedTrace Logo

Targeted Antimalarial Drug Administration for Seasonal Migrant Populations in Amhara Region, Ethiopia

NCT06516042 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 10350

Last updated 2025-05-06

No results posted yet for this study

Summary

The purpose of the study is to assess the effectiveness, feasibility, and acceptability of targeted drug administration for seasonal migrant populations in Metema District, Amhara Region, Ethiopia

Conditions

Interventions

DRUG

Dihydroartemisinin-piperaquine

Participants that provide consent to participate in the TDA and are deemed eligible for treatment will receive a course of dihydroartemisinin-piperaquine (DP) if male, and artemether-lumefantrine (AL) if female. They will take the first dose of the treatment under direct observed therapy, and will receive the rest of the tablets to take on their own for days two and three.

Sponsors & Collaborators

  • Federal Minstry of Health of Ethiopia

    collaborator OTHER_GOV

  • PATH

    lead OTHER

Principal Investigators

  • Adam Bennett, PhD · PATH

  • Henry Ntuku, MD, PhD · PATH

  • Gudissa Assefa Bayissa · Ethiopia Federal Ministry of Health

  • Hiwot Teka · President's Malaria Initiative

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
14 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-08-21
Primary Completion
2025-01-24
Completion
2025-07-31

Countries

  • Ethiopia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06516042 on ClinicalTrials.gov